Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587226 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL4588333 | 0.90 | ALDH1A1 (0.37) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL4588338 | 0.90 | ALDH1A1 (0.37) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL4587822 | 0.83 | MAPT (0.36) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL4587490 | 0.82 | TSHR (0.32) | — | |
| SCHEMBL4587485 | 0.82 | NOD1 (0.35) | — | |
| SCHEMBL4587129 | 0.80 | MAPT (0.35) | SMN1; SMN2 | |
| SCHEMBL4588022 | 0.78 | TACR1 (0.35) | GSTP1GSTM2 | |
| SCHEMBL4588018 | 0.78 | TACR1 (0.35) | GSTP1GSTM2 | |
| SCHEMBL4587151 | 0.76 | NOS2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | CYP1A2 2815/4885CYP2C9 2139/4885CYP2C19 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.